Susquehanna International Group
NGM

Susquehanna International Group’s NGM Biopharmaceuticals, Inc. Common Stock NGM Stock Holding History

Susquehanna International Group’s Portfolio NGM Stock Details NGM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-35,092
Closed -$30.1K – 13707
2023
Q4 		$30.1K Sell
35,092
-48,580
-58% -$42.7K ﹤0.01% 11879
2023
Q3 		$89.5K Buy
83,672
+24,831
+42% +$51.4K ﹤0.01% 11011
2023
Q2 		$152K Sell
58,841
-7,582
-11% -$27K ﹤0.01% 10558
2023
Q1 		$271K Buy
+66,423
New +$307K ﹤0.01% 9945
2022
Q4 		– Sell
-11,768
Closed -$73.8K – 14070
2022
Q3 		$154K Sell
11,768
-851
-7% -$12.9K ﹤0.01% 11204
2022
Q2 		$162K Buy
+12,619
New +$175K ﹤0.01% 10930
2021
Q3 		– Sell
-14,047
Closed -$309K – 13790
2021
Q2 		$277K Buy
+14,047
New +$329K ﹤0.01% 10953
2021
Q1 		– Sell
-13,718
Closed -$384K – 12987
2020
Q4 		$416K Buy
13,718
+2,394
+21% +$52.4K ﹤0.01% 8661
2020
Q3 		$180K Sell
11,324
-809
-7% -$14.8K ﹤0.01% 9553
2020
Q2 		$240K Buy
12,133
+706
+6% +$13.5K ﹤0.01% 8719
2020
Q1 		$141K Buy
+11,427
New +$187K ﹤0.01% 9050

Other funds holding NGM

CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
EC
Euclidean Capital New York $392M AUM 31.85% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TC
Trium Capital London, United Kingdom $163M AUM 45.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group's NGM Position: Q1 2024 in Review

Susquehanna International Group sold out of NGM Biopharmaceuticals, Inc. Common Stock (NGM) in Q1 2024, closing a stake of 35,092 shares — an estimated $30.1K sold.

Susquehanna International Group first reported a position in NGM in Q1 2020 and held it in 11 quarters. The position peaked at $416K in Q4 2020. 75 funds tracked by Wall St. Rank hold NGM as of Q1 2024.

  • Susquehanna International Group reported no remaining NGM Biopharmaceuticals, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Susquehanna International Group sold 35,092 NGM Biopharmaceuticals, Inc. Common Stock shares in Q1 2024, an estimated $30.1K.
  • Susquehanna International Group first reported a position in NGM Biopharmaceuticals, Inc. Common Stock in Q1 2020 and held it in 11 quarters.
  • Susquehanna International Group's NGM Biopharmaceuticals, Inc. Common Stock position peaked at $416K in Q4 2020.
  • 75 funds tracked by Wall St. Rank held NGM Biopharmaceuticals, Inc. Common Stock as of Q1 2024.

Based on Susquehanna International Group's 13F filing for Q1 2024, filed 7 May 2024.